MTOR and gastric cancer: Gambardella and coworkers [61] found that NRF2 amplified the resistance to anti-HER2 drugs through the PI3K/AKT/mTOR/RPS6 pathway, and that ribosomal protein S6 (RPS6) inhibition decreased NRF2 expression and restored sensitivity in HER2-amplified gastric cancer.